Endocrine Abstracts

Background: Extrapulmonary PD NECs carry a poor prognosis. Some studies suggest cisplatin is more appropriate for younger patients due to its increased potency and nephrotoxicity compared to carboplatin, but randomized trials are lacking. We aim to determine whether there is a difference in outcomes for cisplatin vs carboplatin while adjusting for possible confounding factors.Methods: We identified PD NEC patients at Mayo Clinic between 2000-2022. Kaplan...

Background: G3 NETs are a recently recognized entity and although the treatment recommendations largely follow those for grade 1 and 2 NETs, the outcomes of therapy are inferior. Little is known about the optimal therapy sequencing but small studies have suggested a benefit of multikinase inhibitors. Somatostatin analogs, PRRT and chemotherapy have all been reported to have activity but later lines of therapy are needed. In this study, we sought to evaluate the activity of cab...

Background: Poorly differentiated neuroendocrine carcinoma (NEC) is an aggressive malignancy comprising both pulmonary and extrapulmonary primary sites. NEC includes both small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC), as well as other neuroendocrine carcinomas arising from any primary organ. The optimal systemic therapy beyond first line platinum and etoposide is not established. There is a critical need to improve upon the median survival in th...

Background: Poorly differentiated neuroendocrine carcinoma (NEC) is an aggressive malignancy comprising both pulmonary and extrapulmonary primary sites. NEC includes both small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). The optimal systemic therapy beyond first line platinum and etoposide is not established. There is a critical need to improve upon the median survival in the second line, as most patients do not survive more than 6 months. The effi...